Traditional vision assessment methods fail to capture the true impact of geographic atrophy, creating a critical gap between regulatory approval requirements and meaningful patient outcomes. This disconnect threatens access to emerging treatments for a condition that progressively destroys central vision in millions of older adults. Standard visual acuity tests remain largely normal until geographic atrophy reaches advanced stages, when retinal damage has already eliminated much of the macula's photoreceptor layer. The condition's slow, patchy progression means that isolated islands of healthy retina can still process large reading chart letters, masking significant functional decline that patients experience daily. More sensitive assessment tools demonstrate stronger correlations with actual retinal damage patterns. Low luminance visual acuity testing reveals deficits by reducing light levels that expose compromised retinal function. Reading speed measurements capture real-world visual demands more accurately than single-letter recognition. Microperimetry maps precise areas of vision loss, while contrast sensitivity and dark adaptation tests detect early functional changes before structural damage becomes severe. Patient-reported outcome questionnaires provide essential context about how vision changes affect daily activities like driving, reading, and navigating stairs. This comprehensive assessment approach represents a paradigm shift from relying solely on high-contrast letter charts toward multidimensional evaluation that reflects the complex nature of macular degeneration. The review emphasizes targeting rapidly progressing geographic atrophy phenotypes in clinical trials, using multiple functional endpoints rather than traditional acuity measures. This strategy becomes particularly crucial as regulatory agencies increasingly demand proof of functional benefit rather than just anatomical improvement, potentially determining whether promising treatments reach patients who desperately need them.